Central nervous system lymphoma
Pentixapharm AG supports clinical research in central nervous system (CNS) lymphoma, with activity centered on CXCR4-targeted imaging and endoradiotherapy for primary and secondary CNS lymphoma. The sponsor’s trial portfolio in this area includes evaluation of PET/CT approaches for lesion detection and therapeutic studies in patients with CXCR4-positive disease.
- CXCR4-targeted PET/CT imaging
- Endoradiotherapy for CNS lymphoma
- Primary and secondary CNS lymphoma
Clinical interest extends to both diagnostic precision and treatment assessment in lymphoma involving the central nervous system.
Marginal zone lymphoma
The sponsor is also involved in research on recurrent or refractory marginal zone lymphoma, focusing on molecular imaging for staging and lesion characterization. These studies examine the role of Ga-68-labelled PentixaFor PET imaging in identifying disease sites in this lymphoma subtype.
- Staging of marginal zone lymphoma
- Lesion detection by PET imaging
- Recurrent and refractory lymphoma
This area reflects a therapeutic interest in imaging-supported management of indolent B-cell lymphomas.
Oncology imaging
Pentixapharm AG’s research landscape includes oncology imaging with emphasis on positron emission tomography and computed tomography for tumor localization. The sponsor is active in comparing targeted tracers with established imaging methods to improve detection of lymphoma lesions.
- PET/CT-based tumor detection
- Targeted radiotracer imaging
- Lymphoma lesion assessment
Research activity in this field is directed toward imaging strategies relevant to hematologic malignancies.
Radiopharmaceutical therapy
The sponsor funds studies in radiopharmaceutical therapy using yttrium-90-based endoradiotherapy for hematologic malignancies. This therapeutic domain includes investigation of treatment safety, tolerability, and distribution in patients with lymphoma expressing CXCR4.
- Yttrium-90 endoradiotherapy
- Radioligand-based lymphoma treatment
- CXCR4-positive malignancies
The sponsor’s work in this area connects targeted molecular recognition with therapeutic radionuclide delivery.
Hematologic malignancies
Pentixapharm AG’s clinical research is concentrated in hematologic oncology, particularly lymphoma subtypes with unmet imaging and treatment needs. The funded trials address both diagnostic staging and therapeutic evaluation across B-cell lymphoma settings.
- B-cell lymphoma
- Targeted molecular diagnostics
- Lymphoma treatment evaluation
These programs are aligned with clinical development in disease-specific radiopharmaceutical applications.
